UY35483A - Anticuerpos pac1 humanos - Google Patents

Anticuerpos pac1 humanos

Info

Publication number
UY35483A
UY35483A UY35483A UY35483A UY35483A UY 35483 A UY35483 A UY 35483A UY 35483 A UY35483 A UY 35483A UY 35483 A UY35483 A UY 35483A UY 35483 A UY35483 A UY 35483A
Authority
UY
Uruguay
Prior art keywords
pac1
antibodies
human antibodies
binding fragments
antigen
Prior art date
Application number
UY35483A
Other languages
English (en)
Inventor
Xu Cen
Hamburger Agnes Eva
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY35483A publication Critical patent/UY35483A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Anticuerpos y fragmentos de unión al antígeno de los mismos que se unen a la PAC1 humana. También se proveen ácidos nucleicos que codifican los anticuerpos y los fragmentos de unión al antígeno de los mismos, vectores y células que los codifican. Los anticuerpos y los fragmento de unión al antígeno de los mismos pueden inhibir la unión de PAC1 a PACAP, y son de utilidad en numerosos trastornos relacionados con PAC1, incluyendo el tratamiento y/o la prevención de trastornos de cefalea, inclusive la migraña.
UY35483A 2013-03-15 2014-03-17 Anticuerpos pac1 humanos UY35483A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35483A true UY35483A (es) 2014-08-29

Family

ID=50439531

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35483A UY35483A (es) 2013-03-15 2014-03-17 Anticuerpos pac1 humanos

Country Status (24)

Country Link
US (7) US9676851B2 (es)
EP (2) EP2970470B1 (es)
JP (3) JP6283408B2 (es)
KR (1) KR102215405B1 (es)
CN (1) CN105143267B (es)
AP (1) AP2015008732A0 (es)
AR (1) AR095611A1 (es)
AU (2) AU2014228924B2 (es)
CA (1) CA2906737C (es)
CL (1) CL2015002750A1 (es)
CR (1) CR20150575A (es)
EA (1) EA032830B1 (es)
ES (1) ES2770976T3 (es)
HK (2) HK1218554A1 (es)
IL (2) IL241382A0 (es)
MA (1) MA38478A1 (es)
MX (1) MX2015013181A (es)
PE (1) PE20151923A1 (es)
PH (1) PH12015502126A1 (es)
SG (1) SG11201507416WA (es)
TN (1) TN2015000425A1 (es)
TW (2) TW201902931A (es)
UY (1) UY35483A (es)
WO (1) WO2014144632A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194435A1 (en) 2014-09-15 2017-07-26 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016168760A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
SG11202003114UA (en) * 2017-10-04 2020-05-28 Amgen Inc Transthyretin immunoglobulin fusions
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SUBSTITUTION MOLECULES AND THEIR USES
KR20200110362A (ko) * 2018-01-12 2020-09-23 암젠 인크 Pac1 항체 및 이의 용도
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
BR112020020854A2 (pt) 2018-04-12 2021-01-19 Amgen Inc. Métodos para produzir composições de proteínas estáveis
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
CA3227990A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0522159B1 (en) 1990-03-17 2001-12-12 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69131780T2 (de) 1991-03-11 2000-11-16 Univ Georgia Res Foundation At Klonierung und expression der luziferase aus renilla
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
EP0618291A3 (en) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2324648C (en) 1998-03-27 2013-02-26 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
DE69941708D1 (de) 1998-07-20 2010-01-07 Ipsen Pharma Pacap-peptidanaloga
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
EP2048162A4 (en) * 2006-08-08 2010-12-01 Univ Kyoto NEW MONOCLONAL ANTIBODY AND ITS USE
WO2009003489A1 (en) 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
WO2009033489A2 (en) 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CN101434649B (zh) 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
DK2459183T3 (en) 2009-07-27 2016-01-18 Nocicepta Llc Methods for the treatment of pain
CA2775159A1 (en) * 2009-09-25 2011-03-31 Shanghai National Engineering Research Center Of Antibody Medicine Co., Ltd. Method of acquiring proteins with high affinity by computer aided design
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
EP2554669B1 (en) * 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
ES2668895T3 (es) * 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
CN102936303A (zh) * 2011-08-15 2013-02-20 沈阳欧陆科技发展有限公司 一种高氯含量的氯化聚氯乙烯树脂的合成方法
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6419068B2 (ja) 2012-05-21 2018-11-07 ジェネンテック， インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
TW201522375A (zh) 2015-06-16
US10472417B2 (en) 2019-11-12
BR112015023429A2 (pt) 2017-11-28
US20180094055A1 (en) 2018-04-05
KR20150128982A (ko) 2015-11-18
CA2906737C (en) 2023-08-15
TWI636064B (zh) 2018-09-21
MX2015013181A (es) 2015-12-11
WO2014144632A3 (en) 2014-11-20
PH12015502126A1 (en) 2016-01-25
US20150010560A1 (en) 2015-01-08
US10793631B2 (en) 2020-10-06
US20170247451A1 (en) 2017-08-31
EA032830B1 (ru) 2019-07-31
AP2015008732A0 (en) 2015-09-30
TN2015000425A1 (en) 2017-01-03
CN105143267B (zh) 2020-06-26
AU2014228924A1 (en) 2015-10-01
AU2014228924A9 (en) 2016-06-16
WO2014144632A8 (en) 2015-12-30
CA2906737A1 (en) 2014-09-18
US10053507B2 (en) 2018-08-21
SG11201507416WA (en) 2015-10-29
EP2970470B1 (en) 2019-12-04
EP3683237A1 (en) 2020-07-22
US20180362645A1 (en) 2018-12-20
MA38478A1 (fr) 2017-11-30
US20160251432A1 (en) 2016-09-01
HK1218554A1 (zh) 2017-02-24
US20160039939A1 (en) 2016-02-11
CL2015002750A1 (es) 2016-03-04
JP2018076373A (ja) 2018-05-17
KR102215405B1 (ko) 2021-02-10
EA201591791A1 (ru) 2016-03-31
TW201902931A (zh) 2019-01-16
JP6283408B2 (ja) 2018-02-21
JP2016514458A (ja) 2016-05-23
CR20150575A (es) 2016-01-06
AU2014228924B2 (en) 2019-04-18
BR112015023429A8 (pt) 2018-01-23
PE20151923A1 (es) 2016-01-14
US9676851B2 (en) 2017-06-13
WO2014144632A2 (en) 2014-09-18
IL241382A0 (en) 2015-11-30
CN105143267A (zh) 2015-12-09
JP2019024501A (ja) 2019-02-21
EP2970470A2 (en) 2016-01-20
US9822178B2 (en) 2017-11-21
HK1219958A1 (zh) 2017-04-21
JP6443870B2 (ja) 2018-12-26
US20200172614A1 (en) 2020-06-04
AU2019204980A1 (en) 2019-08-01
US9365653B2 (en) 2016-06-14
IL262804A (en) 2018-12-31
US10294298B2 (en) 2019-05-21
ES2770976T3 (es) 2020-07-06
AR095611A1 (es) 2015-10-28

Similar Documents

Publication Publication Date Title
UY35483A (es) Anticuerpos pac1 humanos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CR20170079A (es) Agentes de unión a cd123 y usos de estos
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12017502180A1 (en) Tau-binding antibodies
EA202092435A3 (ru) Моноклональные антитела против bcma
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791093A1 (ru) Антитела к cd47, способы и применение
CY1122978T1 (el) Αντισωματα εναντι-vla-4
DK3177643T3 (da) Bispecifikke T-celle-aktiverende antigenbindende molekyler
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
BR112016022841A2 (pt) cadeia j modificada
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201591454A1 (ru) Связывающие внеклеточный матрикс синтетические пептидогликаны
MY193677A (en) Tau-binding antibodies
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206